| Comparison of the performance of 6 prognostic signatures for estrogen receptor–positive breast cancer: a secondary analysis of a randomized clinical trial I Sestak, R Buus, J Cuzick, P Dubsky, R Kronenwett, C Denkert, S Ferree, ... JAMA oncology 4 (4), 545-553, 2018 | 305 | 2018 |
| Comparison of EndoPredict and EPclin with oncotype DX recurrence score for prediction of risk of distant recurrence after endocrine therapy R Buus, I Sestak, R Kronenwett, C Denkert, P Dubsky, K Krappmann, ... Journal of the National Cancer Institute 108 (11), djw149, 2016 | 232 | 2016 |
| PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer F Brasó-Maristany, S Filosto, S Catchpole, R Marlow, J Quist, ... Nature medicine 22 (11), 1303-1313, 2016 | 223 | 2016 |
| Key role of phosphoinositide 3-kinase class IB in pancreatic cancer CE Edling, F Selvaggi, R Buus, T Maffucci, P Di Sebastiano, H Friess, ... Clinical cancer research 16 (20), 4928-4937, 2010 | 114 | 2010 |
| Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone I Sestak, M Martín, P Dubsky, R Kronenwett, F Rojo, J Cuzick, M Filipits, ... Breast cancer research and treatment 176, 377-386, 2019 | 86 | 2019 |
| Molecular drivers of oncotype DX, prosigna, endopredict, and the breast cancer index: a TransATAC study R Buus, I Sestak, R Kronenwett, S Ferree, CA Schnabel, FL Baehner, ... Journal of Clinical Oncology 39 (2), 126, 2021 | 84 | 2021 |
| Deubiquitinase activities required for hepatocyte growth factor-induced scattering of epithelial cells R Buus, M Faronato, DE Hammond, S Urbé, MJ Clague Current Biology 19 (17), 1463-1466, 2009 | 70 | 2009 |
| Regulation of ErbB2 receptor status by the proteasomal DUB POH1 H Liu, R Buus, MJ Clague, S Urbé PloS one 4 (5), e5544, 2009 | 57 | 2009 |
| Changes in expression of genes representing key biologic processes after neoadjuvant chemotherapy in breast cancer, and prognostic implications in residual disease M Klintman, R Buus, MCU Cheang, A Sheri, IE Smith, M Dowsett Clinical cancer research 22 (10), 2405-2416, 2016 | 56 | 2016 |
| Targeting phosphoinositide 3-kinase pathways in pancreatic cancer-from molecular signalling to clinical trials M Falasca, F Selvaggi, R Buus, S Sulpizio, C E Edling Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2011 | 54 | 2011 |
| Estrogen receptor expression in 21-gene recurrence score predicts increased late recurrence for estrogen-positive/HER2-negative breast cancer M Dowsett, I Sestak, R Buus, E Lopez-Knowles, E Mallon, A Howell, ... Clinical Cancer Research 21 (12), 2763-2770, 2015 | 41 | 2015 |
| Class II phosphoinositide 3-kinase C2β regulates a novel signaling pathway involved in breast cancer progression A Chikh, R Ferro, JJ Abbott, R Piñeiro, R Buus, M Iezzi, F Ricci, ... Oncotarget 7 (14), 18325, 2016 | 32 | 2016 |
| Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors T Muliaditan, L Halim, LM Whilding, B Draper, DY Achkova, F Kausar, ... Cell Reports Medicine 2 (12), 2021 | 28 | 2021 |
| Prognostic value of endopredict in women with hormone receptor–positive, her2-negative invasive lobular breast cancer I Sestak, M Filipits, R Buus, M Rudas, M Balic, M Knauer, R Kronenwett, ... Clinical Cancer Research 26 (17), 4682-4687, 2020 | 24 | 2020 |
| Abstract S6-05: Comprehensive comparison of prognostic signatures for breast cancer in TransATAC I Sestak, R Buus, J Cuzick, P Dubsky, R Kronenwett, S Ferree, D Sgroi, ... Cancer Research 77 (4_Supplement), S6-05-S6-05, 2017 | 21 | 2017 |
| Early enrichment of ESR1 mutations and the impact on gene expression in presurgical primary breast cancer treated with aromatase inhibitors MF Leal, BP Haynes, E Schuster, B Yeo, M Afentakis, L Zabaglo, ... Clinical Cancer Research 25 (24), 7485-7496, 2019 | 20 | 2019 |
| Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer E Crespo-Rodriguez, K Bergerhoff, G Bozhanova, S Foo, EC Patin, ... Journal for ImmunoTherapy of Cancer 8 (2), 2020 | 15 | 2020 |
| Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations E Lopez-Knowles, A Pearson, G Schuster, P Gellert, R Ribas, B Yeo, ... British journal of cancer 120 (2), 247-255, 2019 | 15 | 2019 |
| Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer BP Haynes, O Ginsburg, Q Gao, E Folkerd, M Afentakis, R Buus, ... NPJ breast cancer 5 (1), 42, 2019 | 14 | 2019 |
| Quantitative assessment and prognostic associations of the immune landscape in ovarian clear cell carcinoma S Khalique, S Nash, D Mansfield, J Wampfler, A Attygale, K Vroobel, ... Cancers 13 (15), 3854, 2021 | 13 | 2021 |
Ivana SestakHonorary Assoc. Professor at QMULVerified email at drkrec.com
